Top Page
Feedback
(LSE:FDBK)
Feedback (FDBK) vs. iShares MSCI United Kingdom ETF (EWC)
Feedback Business Overview & Revenue Model
Feedback Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.19M | 1.18M | 1.02M | 588.58K | 287.42K | 449.98K | Gross Profit |
| 603.87K | 144.87K | 131.39K | -63.68K | 213.64K | 417.93K | EBIT |
| -3.54M | -3.69M | -3.40M | -2.51M | -2.04M | -1.40M | EBITDA |
| -2.99M | -2.64M | -2.56M | -1.96M | -2.01M | -1.38M | Net Income Common Stockholders |
| -3.24M | -3.30M | -2.92M | -2.12M | -1.62M | -1.09M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 7.26M | 3.88M | 7.32M | 10.31M | 2.22M | 732.65K | Total Assets |
| 12.20M | 8.34M | 11.72M | 14.30M | 5.82M | 2.50M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -7.26M | -3.88M | -7.32M | -10.31M | -2.22M | -732.65K | Total Liabilities |
| 780.00K | 694.18K | 855.45K | 594.13K | 552.83K | 728.67K | Stockholders Equity |
| 11.41M | 7.64M | 10.87M | 13.71M | 5.27M | 1.77M |
| Cash Flow | Free Cash Flow | ||||
| -2.18M | -2.14M | -2.99M | -2.41M | -3.47M | -1.67M | Operating Cash Flow |
| -2.17M | -2.13M | -1.74M | -1.25M | -2.03M | -786.04K | Investing Cash Flow |
| -1.05M | -1.22M | -1.24M | -1.15M | -1.44M | -883.14K | Financing Cash Flow |
| 5.11M | 0.00 | -830.00 | 10.49M | 4.96M | 1.86M |
Feedback Technical Analysis
Feedback Peers Comparison
Feedback Corporate Events
Feedback plc has announced a trading update for the year ending 31 May 2025, highlighting challenges due to changes in NHS funding and organizational structures, which have delayed expected contract awards. Despite a projected revenue decline to £0.9m, the company remains financially stable with £6.6m in cash and investments. The shift in NHS funding models offers greater flexibility for Feedback’s contracting with Integrated Care Boards (ICBs), aligning with its G-Cloud pricing model. The company is optimistic about future opportunities, particularly in digitization and the NHS’s Neighbourhood Health model, and recently received recognition for its contributions to clinical redesign.
Spark’s Take on GB:FDBK Stock
According to Spark, TipRanks’ AI Analyst, GB:FDBK is a Neutral.
Feedback plc’s stock score reflects a mixture of strengths and challenges. The financial performance is bolstered by a strong balance sheet, but ongoing losses and cash flow issues remain concerns. Technical analysis indicators suggest a bearish trend, while valuation metrics highlight the difficulties in assessing the stock’s worth due to negative earnings. Corporate events provide a positive outlook, with strategic partnerships and funding supporting potential future growth.
To see Spark’s full report on GB:FDBK stock, click here.
Feedback plc has announced its half-year results, highlighting key operational and financial achievements. The company secured a significant contract with Queen Victoria Hospital NHS Foundation Trust and received additional funding to expand its community diagnostic center pilot. Feedback’s Bleepa platform was approved for reimbursement through the Elective Recovery Fund, aligning with the UK government’s focus on NHS reform and elective care. Financially, the company reported a 3% increase in revenue and a 43% rise in sales, alongside a reduced EBITDA loss. Post-period, Feedback operationalized projects in India and continued its strategic alignment with NHS England’s priorities, positioning itself for growth amid evolving market conditions.
Feedback plc has announced that it will release its results for the half year ended 30 November 2024 on 25 February 2025, accompanied by analyst and investor presentations on the same day. These events are significant for stakeholders as they will provide insights into the company’s performance and future prospects, potentially impacting its market positioning and growth trajectory.